StreetInsider.com News Articles

Form 4 Ultragenyx Pharmaceutica For: Jun 01 Filed by: Horn Howard

Mon, 01 Jun 2026 19:12:00 -0400

si-local-file:///var/storage/secattach/20260601/26585547.html

Form 4 Ultragenyx Pharmaceutica For: Jun 01 Filed by: Horn Howard

Mon, 01 Jun 2026 19:12:00 -0400

si-local-file:///var/storage/secattach/20260601/26585547.html

Form 144 Ultragenyx Pharmaceutica Filed by: Horn Howard

Mon, 01 Jun 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260601/26583605.html

Form 144 Ultragenyx Pharmaceutica Filed by: Horn Howard

Mon, 01 Jun 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260601/26583605.html

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Fri, 22 May 2026 16:30:00 -0400

NOVATO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 17,567 restricted stock units of the company’s common stock to 11 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of May 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Fri, 22 May 2026 16:30:00 -0400

Ultragenyx Pharma (RARE) PT Raised to $96 at Cantor Fitzgerald

Thu, 21 May 2026 06:36:39 -0400

Cantor Fitzgerald analyst Kristen Kluska raised the price target on Ultragenyx Pharma (NASDAQ: RARE) to $96.00 (from $84.00) while maintaining a Overweight rating.

The analyst comments "When we originally launched coverage of RARE, the majority of our thesis was on setrusumab for osteogenesis imperfecta, a call we recognize we were wrong on. ● Our original thesis was very conservative on GTX-102 for Angelman syndrome. ● Over the last two months, we have spent significant time diving deeper into this program with our deep dive (link), and virtual Angelman syndrome week: Day 1 (link), Day 2 (link), Day 3 (link), Day 4

Ultragenyx Pharma (RARE) PT Raised to $96 at Cantor Fitzgerald

Thu, 21 May 2026 06:36:39 -0400

Cantor Fitzgerald analyst Kristen Kluska raised the price target on Ultragenyx Pharma (NASDAQ: RARE) to $96.00 (from $84.00) while maintaining a Overweight rating.

Ultragenyx Pharma (RARE) PT Lowered to $72 at JPMorgan

Wed, 20 May 2026 07:37:21 -0400

JPMorgan analyst Anupam Rama lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $72.00 (from $74.00) while maintaining a Overweight rating.

Form 4 Ultragenyx Pharmaceutica For: May 14 Filed by: Fust Matthew K

Mon, 18 May 2026 18:51:00 -0400

si-local-file:///var/storage/secattach/20260518/26515552.html

Form 4 Ultragenyx Pharmaceutica For: May 14 Filed by: Fust Matthew K

Mon, 18 May 2026 18:51:00 -0400

si-local-file:///var/storage/secattach/20260518/26515552.html

Form 4 Ultragenyx Pharmaceutica For: May 14 Filed by: SULIMAN SHEHNAAZ

Mon, 18 May 2026 18:41:00 -0400

si-local-file:///var/storage/secattach/20260518/26515526.html

Form 4 Ultragenyx Pharmaceutica For: May 14 Filed by: SULIMAN SHEHNAAZ

Mon, 18 May 2026 18:41:00 -0400

si-local-file:///var/storage/secattach/20260518/26515526.html

Form 4 Ultragenyx Pharmaceutica For: May 14 Filed by: Ray Amrit

Mon, 18 May 2026 18:40:00 -0400

si-local-file:///var/storage/secattach/20260518/26515523.html

Form 4 Ultragenyx Pharmaceutica For: May 14 Filed by: Ray Amrit

Mon, 18 May 2026 18:40:00 -0400

si-local-file:///var/storage/secattach/20260518/26515523.html

Form 4 Ultragenyx Pharmaceutica For: May 14 Filed by: Sanders Corazon (Corsee) D.

Mon, 18 May 2026 18:38:00 -0400

si-local-file:///var/storage/secattach/20260518/26515519.html

Form 4 Ultragenyx Pharmaceutica For: May 14 Filed by: Sanders Corazon (Corsee) D.

Mon, 18 May 2026 18:38:00 -0400

si-local-file:///var/storage/secattach/20260518/26515519.html

Form 4 Ultragenyx Pharmaceutica For: May 14 Filed by: NARACHI MICHAEL

Mon, 18 May 2026 18:36:00 -0400

si-local-file:///var/storage/secattach/20260518/26515513.html

Form 4 Ultragenyx Pharmaceutica For: May 14 Filed by: NARACHI MICHAEL

Mon, 18 May 2026 18:36:00 -0400

si-local-file:///var/storage/secattach/20260518/26515513.html

Form 4 Ultragenyx Pharmaceutica For: May 14 Filed by: WELCH DANIEL G

Mon, 18 May 2026 18:23:00 -0400

si-local-file:///var/storage/secattach/20260518/26515484.html

Form 4 Ultragenyx Pharmaceutica For: May 14 Filed by: WELCH DANIEL G

Mon, 18 May 2026 18:23:00 -0400

si-local-file:///var/storage/secattach/20260518/26515484.html

Form 4 Ultragenyx Pharmaceutica For: May 14 Filed by: Dunsire Deborah

Mon, 18 May 2026 18:21:00 -0400

si-local-file:///var/storage/secattach/20260518/26515479.html

Form 4 Ultragenyx Pharmaceutica For: May 14 Filed by: Dunsire Deborah

Mon, 18 May 2026 18:21:00 -0400

si-local-file:///var/storage/secattach/20260518/26515479.html

Form 144 Ultragenyx Pharmaceutica Filed by: SULIMAN SHEHNAAZ

Mon, 18 May 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260518/26514724.html

Form 144 Ultragenyx Pharmaceutica Filed by: SULIMAN SHEHNAAZ

Mon, 18 May 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260518/26514724.html